Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
Because of its frequent occurrence, poor prognosis, low quality of life of patients accompanying the disease and high costs associated with treatment heart failure is a significant health problem in modern cardiology. The treatment of patients with heart failure and reduced ejection fraction (HFrEF)...
Guardado en:
Autor principal: | |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7df11093d00449928650f3e7ff95d42c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:7df11093d00449928650f3e7ff95d42c |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:7df11093d00449928650f3e7ff95d42c2021-12-02T19:19:13ZDapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach1734-93381897-429510.5114/aic.2021.107491https://doaj.org/article/7df11093d00449928650f3e7ff95d42c2021-07-01T00:00:00Zhttps://www.termedia.pl/Dapagliflozin-in-the-treatment-of-patients-with-heart-failure-with-reduced-left-ventricular-ejection-fraction-a-practical-approach,35,44586,1,1.htmlhttps://doaj.org/toc/1734-9338https://doaj.org/toc/1897-4295Because of its frequent occurrence, poor prognosis, low quality of life of patients accompanying the disease and high costs associated with treatment heart failure is a significant health problem in modern cardiology. The treatment of patients with heart failure and reduced ejection fraction (HFrEF) is supported by large-scale randomized clinical trials (RCTs), reflected in the ESC/HFA treatment recommendations. The use of -blockers, inhibitors of the renin-angiotensin aldosterone system (RAA), including angiotensin converting enzyme ACE/ARB inhibitors, angiotensin and neprilysin receptor blockers (ARNI) and mineralocorticoid receptor antagonists (MRA) have been a solid basis for triple HFrEF therapy over the last few years, partially altering the natural history of patients with HF. Despite this, the 5-year survival rate in HF is still lower than for some types of cancer. Therefore, the search for new drugs to improve the prognosis of this disease is still ongoing. A new group of drugs – the so-called flozins, i.e. – is a great hope for a change in the natural history of heart failure. The following article presents practical aspects of using these drugs in the treatment of patients with HFrEF, taking into account both the inclusion criteria and various clinical profiles of patients.Jadwiga NesslerTermedia Publishing Housearticleheart failure with reduced left ventricular ejection fraction (hfref) flozins – sodium-glucose cotransporter type 2 (sglt-2) inhibitors (sglt 2) dapagliflozin indications for use patients’ clinical profiles.MedicineRENAdvances in Interventional Cardiology, Vol 17, Iss 2, Pp 135-140 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
heart failure with reduced left ventricular ejection fraction (hfref) flozins – sodium-glucose cotransporter type 2 (sglt-2) inhibitors (sglt 2) dapagliflozin indications for use patients’ clinical profiles. Medicine R |
spellingShingle |
heart failure with reduced left ventricular ejection fraction (hfref) flozins – sodium-glucose cotransporter type 2 (sglt-2) inhibitors (sglt 2) dapagliflozin indications for use patients’ clinical profiles. Medicine R Jadwiga Nessler Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach |
description |
Because of its frequent occurrence, poor prognosis, low quality of life of patients accompanying the disease and high costs associated with treatment heart failure is a significant health problem in modern cardiology. The treatment of patients with heart failure and reduced ejection fraction (HFrEF) is supported by large-scale randomized clinical trials (RCTs), reflected in the ESC/HFA treatment recommendations. The use of -blockers, inhibitors of the renin-angiotensin aldosterone system (RAA), including angiotensin converting enzyme ACE/ARB inhibitors, angiotensin and neprilysin receptor blockers (ARNI) and mineralocorticoid receptor antagonists (MRA) have been a solid basis for triple HFrEF therapy over the last few years, partially altering the natural history of patients with HF. Despite this, the 5-year survival rate in HF is still lower than for some types of cancer. Therefore, the search for new drugs to improve the prognosis of this disease is still ongoing. A new group of drugs – the so-called flozins, i.e. – is a great hope for a change in the natural history of heart failure. The following article presents practical aspects of using these drugs in the treatment of patients with HFrEF, taking into account both the inclusion criteria and various clinical profiles of patients. |
format |
article |
author |
Jadwiga Nessler |
author_facet |
Jadwiga Nessler |
author_sort |
Jadwiga Nessler |
title |
Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach |
title_short |
Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach |
title_full |
Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach |
title_fullStr |
Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach |
title_full_unstemmed |
Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach |
title_sort |
dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach |
publisher |
Termedia Publishing House |
publishDate |
2021 |
url |
https://doaj.org/article/7df11093d00449928650f3e7ff95d42c |
work_keys_str_mv |
AT jadwiganessler dapagliflozininthetreatmentofpatientswithheartfailurewithreducedleftventricularejectionfractionapracticalapproach |
_version_ |
1718376860810739712 |